Cadralazine Chemical Properties

Melting point:

160-162°

Boiling point:

425.88°C (rough estimate)

Density 

1.1585 (rough estimate)

refractive index 

1.6500 (estimate)

storage temp. 

2-8°C

solubility 

DMSO : 250 mg/mL (882.36 mM; ultrasonic and warming and heat to 60°C)

pka

6.0(at 25℃)

CAS DataBase Reference

64241-34-5

Safety Information

Toxicity

LD50 in rats, dogs (mg/kg): 269, approx 400 i.v.; 2060, >2000 orally (Semeraro); in mice (mg/kg): 700 i.p. (Parravicini)

Cadralazine Usage And Synthesis

Description

Cadralazine is a vasodilatory antihypertensive reportedly better-tolerated and longer-acting than hydralazine. It is useful as a second-line treatment in the management of hypertension.

Originator

ISF;（Smith Mine) (Italy)

Definition

ChEBI: Cadralazine is an organic molecular entity.

brand name

Cadraten 21 cpr 20 mg;Cadraten 30 cpr 10 mg;Cadraten 30 cpr 15 mg;Cadratin;Cadrilan.

World Health Organization (WHO)

Cadralazine, a peripheral vasodilator, was introduced in 1989 for the treatment of arterial hypertension.In 1992, its association with serious side effects led to the refusal of registration in Norway. Animal experiments have demonstrated drug-related impairment of thyroid function as well as potential carcinogenicity and genotoxicity. It remains available for treatment of hypertension in Italy.

Cadralazine(64241-34-5)Related Product Information

• 5-Aminosalicylic acid
• Terazosin hydrochloride capsule
• Chrysene
• 3,6-Pyridazinediamine(9CI)
• 3-Hydrazino-6-((2-hydroxypropyl)methylamino)pyridazine dihydrochloride
• Cadralazine
• Hydrazinecarboxylic acid, 2-(6-((2-hydroxypropyl)methylamino)-3-pyrida zinyl)-, ethyl ester